Osiris Therapeutics, Inc. (NASDAQ:OSIR)
| CAPS Rating |
|
|---|---|
| Open | $4.95 |
| Previous Close | $5.03 |
| Daily Range | $4.76 - $4.99 |
| 52-Week Range | $4.12 - $8.39 |
| Market Cap | $158.21M |
| P/E Ratio | 11.00 |
| Dividend (Yield) | N/A (N/A) |
| Volume | 103,043 |
| Average Daily Volume | 0 |
OSIR
VS S&P 500 (SPY)
How do you think OSIR will perform against the market?
Caps
Motley Fool CAPS is a community working together to find better stocks and to become better investors.
OSIR Advanced Details
- CAPS Community Analysis: Commentary, Scorecard
- Advanced Financial Analysis: Historical Prices, Chart, Stats, Ratios, Earnings/Growth Rates, Statements, SEC Filings
OSIR News and Commentary
- Osiris Provides Update on Sanofi Deal - Analyst Blog – NASDAQ
- Osiris' Update on Prochymal - Analyst Blog – NASDAQ
- Stem-Cell Stocks May Now Be Worth The Risk – SmartMoney
- I Called the 10% rise of Osiris Therapeutics – Blog at The Motley Fool
- Ascending Triangle-Osiris Therapeutics – Blog at The Motley Fool
- Why Did My Stock Just Die? – The Motley Fool
- Companies Positioned for Treating Acute Radiation Syndrome – SeekingAlpha
- 25 Small Caps With Sales and EPS Declining in 2012 – SeekingAlpha
- 10K filing by OSIR shows it can help Japan with Radiation exposure treatment. – Blog at The Motley Fool
- Radiation Drug Maker Cleveland BioLabs Rises On Japan Concerns – SmartMoney
- Earthquake Highlights Opportunity for Treating Radiation Sickness – SeekingAlpha
- 12 Small-Cap Biotech Stocks Being Snapped Up by Mutual Fund Investors – The Motley Fool
- An Inside Look at Biotech Investing, Part 2 – The Motley Fool
- Sanofi Deal Brings Risk, Opportunity To Genzyme Partners – SmartMoney
- Beware the Lady Gaga Effect on Growth or Rebound Stocks – SeekingAlpha
- 1 Great Stock That Analysts Snub – The Motley Fool
- Osiris: Finding Opportunity Amongst Uncertainty – SeekingAlpha
- Osiris: Opportunity Amidst Uncertainty – SeekingAlpha
- Unintended Consequences: Foreclosure Edition – Blog at The Motley Fool
- Court Decision Puts Pressure on Embryonic Stem Cell Stocks – SeekingAlpha
RSS Headlines
Fool UK
